AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge
12 Oktober 2023 - 8:05AM
Business Wire
R&D Postdoctoral Challenge is a
ground-breaking initiative fostering collaboration, innovation and
global diversity
AstraZeneca announced today eight winners of the 2023 R&D
Postdoctoral Challenge and agreed to fund their postdoctoral
positions at one of the Company’s strategic R&D centres in
either Cambridge, UK, Gaithersburg or Boston, US or Gothenburg,
Sweden.
The R&D Postdoctoral Challenge stands out among traditional
industry postdoctoral initiatives which usually offer pre-defined
projects. The unique programme from AstraZeneca, now running for a
second year, enables early-career scientists from anywhere in the
world to submit and potentially pursue their own novel research
proposals within the Company. With the support of highly skilled
and multidisciplinary research teams, the winners will pursue their
unique research projects to ultimately accelerate drug discovery
for some of the world’s most complex rare and chronic diseases. By
encouraging diverse thinking and global collaboration, AstraZeneca
pushes the boundaries of science to deliver life-changing
medicines.
After being short-listed from nearly 100 applicants, eight
finalists presented their research proposals in a live event at
AstraZeneca’s Discovery Centre (DISC), located in Cambridge, UK.
After presenting to a judging panel comprising AstraZeneca and
external life science leaders, the winners were selected based on
scientific merit and potential to create a real impact for
patients.
Dr Jenni Nordborg, Director, International Affairs, Lif said: “I
was captivated by the pitches and seeing the novel approaches that
each and every one of the finalists presented on stage. But even
more than that, I was inspired by their enthusiasm and passion for
their focus area of science, and their commitment to research that
will improve outcomes for patients.”
Dr Sharon Barr, Executive Vice President, BioPharmaceuticals
R&D, AstraZeneca, said: “Scientific progress depends on our
ability to foster a community that encourages new ideas and fresh
perspectives from the next generation of leading scientists. We are
thrilled to welcome the eight winners to AstraZeneca; this unique
programme demonstrates our commitment to supporting early talent
and science led innovation.”
Dr Seng Cheng, Senior Vice President, Research and Product
Development, Alexion, said: “The winners are all united by their
willingness to step away from the norm and pursue a programme that
is completely changing the traditional postdoc scheme. They bring
the passion and enthusiasm to innovate, as well a collective
ambition to accelerate drug discovery.”
With fully funded AstraZeneca postdoctoral research positions,
the winners gain access to the Company’s expertise, compounds,
novel tools and technologies, as well as mentoring support to turn
their innovative ideas into solutions that could benefit patients
around the world.
As part of AstraZeneca’s Early Talent programmes, the R&D
Postdoctoral Challenge supports the commitment to early career
scientists by nurturing talent and providing opportunities to work
within a diverse and inclusive environment that enables science to
thrive.
Notes
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team,
please click here. For Media contacts, click here.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231011003940/en/
Brendan McEvoy 1-302-885-2677
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024